Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H11F2N3O4 |
Molecular Weight | 263.1985 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1cn([C@@]2([H])C([C@@]([H])([C@@]([H])(CO)O2)O)(F)F)c(nc1=N)O
InChI
InChIKey=SDUQYLNIPVEERB-QPPQHZFASA-N
InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
Molecular Formula | C9H11F2N3O4 |
Molecular Weight | 263.1985 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00441http://adisinsight.springer.com/drugs/800025123 | https://www.ncbi.nlm.nih.gov/pubmed/20066470 | https://www.ncbi.nlm.nih.gov/pubmed/22002019Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020509s075lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00441http://adisinsight.springer.com/drugs/800025123 | https://www.ncbi.nlm.nih.gov/pubmed/20066470 | https://www.ncbi.nlm.nih.gov/pubmed/22002019
Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020509s075lbl.pdf
Gemcitabine elaidate is an ester of anticancer drug gemcitabine and elaidic fatty acid. The motivation to make an ester was to facilitate gemcitabine uptake and prolong retention in the cell. The drug is converted to parent compound gemcitabine both inside and outside the cell. Gemcitabine elaidate was developed by Clavis Pharma for treatment of solid tumors, including non-small cell lung cancer and pancreatic cancer, but its development was discontinued after product missed the primary endpoint in the Phase II LEAP trial to treat metastatic pancreatic cancer.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11391856
Curator's Comment:: modest penetration of gemcitabine into the CSF after i.v. administration in nonhuman primates was shown, also can partially cross the BBB in humans https://www.ncbi.nlm.nih.gov/pubmed/17538177
Originator
Sources: http://adisinsight.springer.com/drugs/800000811http://adisinsight.springer.com/drugs/800025123
Curator's Comment:: # Eli Lilly; University of Innsbruck
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map03030 |
|||
Target ID: CHEMBL1830 Sources: http://www.drugbank.ca/drugs/DB00441 |
|||
Target ID: DNA Sources: http://www.drugbank.ca/drugs/DB00441 |
|||
Target ID: CHEMBL614774 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25833690 |
3.0 nM [IC50] | ||
Target ID: CHEMBL614067 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25833690 |
30.0 nM [IC50] | ||
Target ID: CHEMBL614139 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25517919 |
10.0 nM [IC50] | ||
Target ID: CHEMBL614725 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25517919 |
7.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Gemzar Approved UseGemzar is a nucleoside metabolic inhibitor indicated:
• in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after
completion of platinum- based therapy.
• in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing
adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
• in combination with cisplatin for the treatment of non-small cell lung cancer.
• as a single agent for the treatment of pancreatic cancer. Launch Date8.3203201E11 |
|||
Primary | Gemzar Approved UseGemzar is a nucleoside metabolic inhibitor indicated:
• in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after
completion of platinum- based therapy.
• in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing
adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
• in combination with cisplatin for the treatment of non-small cell lung cancer.
• as a single agent for the treatment of pancreatic cancer. Launch Date8.3203201E11 |
|||
Primary | Gemzar Approved UseGemzar is a nucleoside metabolic inhibitor indicated:
• in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after
completion of platinum- based therapy.
• in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing
adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
• in combination with cisplatin for the treatment of non-small cell lung cancer.
• as a single agent for the treatment of pancreatic cancer. Launch Date8.3203201E11 |
|||
Primary | Gemzar Approved UseGemzar is a nucleoside metabolic inhibitor indicated:
• in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after
completion of platinum- based therapy.
• in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing
adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
• in combination with cisplatin for the treatment of non-small cell lung cancer.
• as a single agent for the treatment of pancreatic cancer. Launch Date8.3203201E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
229 nM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122 |
75 mg/m² 1 times / week multiple, intravenous dose: 75 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
GEMCITABINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
263.6 nM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122 |
135 mg/m² 1 times / week multiple, intravenous dose: 135 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
GEMCITABINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
292.5 nM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122 |
180 mg/m² 1 times / week multiple, intravenous dose: 180 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
GEMCITABINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3526.4 nM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122 |
75 mg/m² 1 times / week multiple, intravenous dose: 75 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
GEMCITABINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4818.5 nM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122 |
135 mg/m² 1 times / week multiple, intravenous dose: 135 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
GEMCITABINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4863.4 nM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19556122 |
180 mg/m² 1 times / week multiple, intravenous dose: 180 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
GEMCITABINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5700 mg/m2 1 times / 2 weeks multiple, intravenous MTD Dose: 5700 mg/m2, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 5700 mg/m2, 1 times / 2 weeks Sources: |
unhealthy, 55 years (range: 34-71 years) n = 4 Health Status: unhealthy Age Group: 55 years (range: 34-71 years) Sex: M+F Population Size: 4 Sources: |
Other AEs: Myelosuppression, Paresthesia... Other AEs: Myelosuppression Sources: Paresthesia Rash (severe) |
2200 mg/m2 3 times / 4 weeks multiple, intravenous MTD Dose: 2200 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 2200 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, 58 years (range: 40-77 years) n = 6 Health Status: unhealthy Condition: Non-Small-Cell Lung Cancer Age Group: 58 years (range: 40-77 years) Sex: M+F Population Size: 6 Sources: |
Other AEs: Neutropenia, AST increased... Other AEs: Neutropenia (grade 2, 1 patient) Sources: AST increased (grade 2, 1 patient) ALT increased (grade 2, 1 patient) |
2800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 2800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 2800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, 58 years (range: 40-77 years) n = 5 Health Status: unhealthy Condition: Non-Small-Cell Lung Cancer Age Group: 58 years (range: 40-77 years) Sex: M+F Population Size: 5 Sources: |
DLT: Hepatotoxicity, Neutropenic infection... Dose limiting toxicities: Hepatotoxicity (grade 3, 2 patients) Sources: Neutropenic infection (grade 4, 1 patient) |
1000 mg/m2 3 times / 4 weeks multiple, intravenous Recommended Dose: 1000 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, 74 years n = 1 Health Status: unhealthy Age Group: 74 years Sex: M Population Size: 1 Sources: |
Disc. AE: Necrosis skin... AEs leading to discontinuation/dose reduction: Necrosis skin (1 patient) Sources: |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Disc. AE: Myocardial infarction, Cerebrovascular accident... AEs leading to discontinuation/dose reduction: Myocardial infarction (2%) Sources: Cerebrovascular accident (2%) Arrhythmia (2%) Hypertension (2%) Anemia (<1%) Thrombocytopenia (<1%) Hepatic dysfunction NOS (<1%) Kidney dysfunction (<1%) Nausea (<1%) Vomiting (<1%) Fever (<1%) Rash (<1%) Dyspnea (<1%) Hemorrhage (<1%) Infection (<1%) Stomatitis (<1%) Somnolence (<1%) Flu syndrome (<1%) Edema (<1%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Myelosuppression | 5700 mg/m2 1 times / 2 weeks multiple, intravenous MTD Dose: 5700 mg/m2, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 5700 mg/m2, 1 times / 2 weeks Sources: |
unhealthy, 55 years (range: 34-71 years) n = 4 Health Status: unhealthy Age Group: 55 years (range: 34-71 years) Sex: M+F Population Size: 4 Sources: |
|
Paresthesia | 5700 mg/m2 1 times / 2 weeks multiple, intravenous MTD Dose: 5700 mg/m2, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 5700 mg/m2, 1 times / 2 weeks Sources: |
unhealthy, 55 years (range: 34-71 years) n = 4 Health Status: unhealthy Age Group: 55 years (range: 34-71 years) Sex: M+F Population Size: 4 Sources: |
|
Rash | severe | 5700 mg/m2 1 times / 2 weeks multiple, intravenous MTD Dose: 5700 mg/m2, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 5700 mg/m2, 1 times / 2 weeks Sources: |
unhealthy, 55 years (range: 34-71 years) n = 4 Health Status: unhealthy Age Group: 55 years (range: 34-71 years) Sex: M+F Population Size: 4 Sources: |
ALT increased | grade 2, 1 patient | 2200 mg/m2 3 times / 4 weeks multiple, intravenous MTD Dose: 2200 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 2200 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, 58 years (range: 40-77 years) n = 6 Health Status: unhealthy Condition: Non-Small-Cell Lung Cancer Age Group: 58 years (range: 40-77 years) Sex: M+F Population Size: 6 Sources: |
AST increased | grade 2, 1 patient | 2200 mg/m2 3 times / 4 weeks multiple, intravenous MTD Dose: 2200 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 2200 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, 58 years (range: 40-77 years) n = 6 Health Status: unhealthy Condition: Non-Small-Cell Lung Cancer Age Group: 58 years (range: 40-77 years) Sex: M+F Population Size: 6 Sources: |
Neutropenia | grade 2, 1 patient | 2200 mg/m2 3 times / 4 weeks multiple, intravenous MTD Dose: 2200 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 2200 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, 58 years (range: 40-77 years) n = 6 Health Status: unhealthy Condition: Non-Small-Cell Lung Cancer Age Group: 58 years (range: 40-77 years) Sex: M+F Population Size: 6 Sources: |
Hepatotoxicity | grade 3, 2 patients DLT |
2800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 2800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 2800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, 58 years (range: 40-77 years) n = 5 Health Status: unhealthy Condition: Non-Small-Cell Lung Cancer Age Group: 58 years (range: 40-77 years) Sex: M+F Population Size: 5 Sources: |
Neutropenic infection | grade 4, 1 patient DLT |
2800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 2800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 2800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, 58 years (range: 40-77 years) n = 5 Health Status: unhealthy Condition: Non-Small-Cell Lung Cancer Age Group: 58 years (range: 40-77 years) Sex: M+F Population Size: 5 Sources: |
Necrosis skin | 1 patient Disc. AE |
1000 mg/m2 3 times / 4 weeks multiple, intravenous Recommended Dose: 1000 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, 74 years n = 1 Health Status: unhealthy Age Group: 74 years Sex: M Population Size: 1 Sources: |
Arrhythmia | 2% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Cerebrovascular accident | 2% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Hypertension | 2% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Myocardial infarction | 2% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Anemia | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Dyspnea | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Edema | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Fever | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Flu syndrome | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Hemorrhage | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Hepatic dysfunction NOS | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Infection | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Kidney dysfunction | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Nausea | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Rash | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Somnolence | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Stomatitis | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Thrombocytopenia | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Vomiting | <1% Disc. AE |
800 mg/m2 3 times / 4 weeks multiple, intravenous Dose: 800 mg/m2, 3 times / 4 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 3 times / 4 weeks Sources: |
unhealthy, adult n = 979 Health Status: unhealthy Condition: malignancies Age Group: adult Sex: M+F Population Size: 979 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.nature.com/articles/6601011/ Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Treatment of classical Kaposi's sarcoma with gemcitabine. | 2001 |
|
Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. | 2001 |
|
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. | 2001 |
|
Treatment of extensive stage small cell lung cancer. | 2001 |
|
Lung cancer: therapeutic options for stage IV and recurrent NSCLC. | 2001 |
|
Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer. | 2001 |
|
Options in advanced non-small cell lung cancer: a review and report on a phase II study of vinorelbine plus gemcitabine. | 2001 |
|
Neoadjuvant, adjuvant, and palliative treatment of pancreatic cancer. | 2001 Apr |
|
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. | 2001 Apr |
|
[Medical treatment of pulmonary neoplasms]. | 2001 Feb |
|
Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer. | 2001 Feb |
|
Gemcitabine and Pemetrexed disodium in treating breast cancer. | 2001 Feb |
|
Gemcitabine plus cisplatin in breast cancer. | 2001 Feb |
|
Treatment of advanced breast cancer with gemcitabine and vinorelbine. | 2001 Feb |
|
Gemcitabine as single-agent therapy in the management of advanced breast cancer. | 2001 Feb |
|
Chemotherapy agents in transitional cell carcinoma: the old and the new. | 2001 Feb |
|
Effects of gemcitabine on cisplatin-induced nephrotoxicity in rats: schedule-dependent study. | 2001 Feb |
|
End-joining deficiency and radiosensitization induced by gemcitabine. | 2001 Feb 15 |
|
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. | 2001 Feb 15 |
|
Gemcitabine and cisplatin for advanced, metastatic bladder cancer. | 2001 Feb 15 |
|
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. | 2001 Feb 15 |
|
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. | 2001 Feb-Mar |
|
Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings. | 2001 Jan |
|
Phase I trial of gemcitabine in patients with advanced pancreatic cancer. | 2001 Jan |
|
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. | 2001 Jan |
|
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). | 2001 Jan |
|
Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer. | 2001 Jan |
|
Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan. | 2001 Jan |
|
Anticancer drug-induced kidney disorders. | 2001 Jan |
|
[Refractory non-small-cell lung cancer responding to combination chemotherapy with docetaxel, gemcitabine and cisplatin]. | 2001 Jan |
|
Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. | 2001 Jan |
|
Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study. | 2001 Jan 15 |
|
Novel approaches in the treatment of non-small-cell lung cancer. | 2001 Mar |
|
Treatment of elderly patients with non-small-cell lung cancer. | 2001 Mar |
|
Optimizing chemoradiation in locally advanced non-small-cell lung cancer. | 2001 Mar |
|
Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer. | 2001 Mar |
|
Gemcitabine for the treatment of non-small-cell lung cancer. | 2001 Mar |
|
Triplet combination chemotherapy and targeted therapy regimens. | 2001 Mar |
|
Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. | 2001 Mar |
|
Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial. | 2001 Mar |
|
Latent hematopoietic stem cell toxicity associated with protracted drug administration. | 2001 Mar |
|
[A case of primary malignant hemangiopericytoma of the lung with marked response to combination chemotherapy with cisplatin, ifosfamide and gemcitabine]. | 2001 Mar |
|
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. | 2001 Mar |
|
Optimizing chemoradiation therapy approaches to unresectable stage III non--small cell lung cancer. | 2001 Mar |
|
Predictive molecular markers in non-small cell lung cancer. | 2001 Mar |
|
Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. | 2001 Mar 1 |
|
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. | 2001 Mar 15 |
|
Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells. | 2001 Mar 23 |
|
Cotton-wool spots associated with pancreatic carcinoma. | 2001 Mar 26 |
|
Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. | 2001 May 4 |
Sample Use Guides
For intravenous use only.
• Ovarian Cancer: 1000 mg/m2 over 30 minutes on Days 1 and 8 of
each 21-day cycle. (2.1)
• Breast Cancer: 1250 mg/m2
over 30 minutes on Days 1 and 8 of
each 21-day cycle. (2.2)
• Non-Small Cell Lung Cancer: 1000 mg/m2
over 30 minutes on
Days 1, 8, and 15 of each 28-day cycle or 1250 mg/m2
over 30
minutes on Days 1 and 8 of each 21-day cycle. (2.3)
• Pancreatic Cancer: 1000 mg/m2
over 30 minutes once weekly for
the first 7 weeks, then one week rest, then once weekly for 3
weeks of each 28-day cycle
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25517919
Treatment of PANC-1 cells with gemcitabine (10 nM) increased the percentage
of cells in S phase to 60.1±6.0% and reduced the percentage in the G0/G1 phase to 28.7±4.2%
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 03:34:51 UTC 2021
by
admin
on
Sat Jun 26 03:34:51 UTC 2021
|
Record UNII |
B76N6SBZ8R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QL01BC05
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
WHO-ATC |
L01BC05
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
FDA ORPHAN DRUG |
477015
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
NCI_THESAURUS |
C2150
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
FDA ORPHAN DRUG |
504815
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
FDA ORPHAN DRUG |
620917
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
NDF-RT |
N0000000233
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
NCI_THESAURUS |
C1557
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
FDA ORPHAN DRUG |
476915
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
NDF-RT |
N0000175595
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
LIVERTOX |
451
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
FDA ORPHAN DRUG |
737820
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
||
|
FDA ORPHAN DRUG |
502015
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07892MIG
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
7567
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
GEMCITABINE
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
12574
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | RxNorm | ||
|
M5690
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | Merck Index | ||
|
95058-81-4
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
B76N6SBZ8R
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
DB00441
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
6515
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
Gemcitabine
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
60750
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
1283
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
C66876
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
95058-81-4
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
CHEMBL888
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
C056507
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
4793
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
PRIMARY | |||
|
103882-84-4
Created by
admin on Sat Jun 26 03:34:51 UTC 2021 , Edited by admin on Sat Jun 26 03:34:51 UTC 2021
|
NON-SPECIFIC STEREOCHEMISTRY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
Km
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE |
kcat
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
kcat
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
can be extracted from peripheral blood mononuclear cells.
|
||
|
METABOLITE INACTIVE -> PARENT |
PLASMA; URINE
|
||
|
METABOLITE -> PARENT | |||
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |